Rapport Therapeutics, Inc. (RAPP)
NASDAQ: RAPP · Real-Time Price · USD
33.74
-1.66 (-4.69%)
At close: Apr 28, 2026, 4:00 PM EDT
33.09
-0.65 (-1.93%)
After-hours: Apr 28, 2026, 5:37 PM EDT

Rapport Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
Selling, General & Admin
30.3122.128.181.37
Research & Development
94.7960.94284.49
Operating Expenses
125.183.0636.185.85
Operating Income
-125.1-83.06-36.18-5.85
Interest Expense
----0.31
Interest & Investment Income
13.6212.142.53-
EBT Excluding Unusual Items
-111.48-70.92-33.65-6.17
Other Unusual Items
--7.39-1.12-
Pretax Income
-111.48-78.31-34.78-11.62
Income Tax Expense
--0.01-
Net Income
-111.48-78.31-34.79-11.62
Net Income to Common
-111.48-78.31-34.79-11.62
Shares Outstanding (Basic)
392121
Shares Outstanding (Diluted)
392121
Shares Change (YoY)
87.74%1277.25%93.74%-
EPS (Basic)
-2.86-3.78-23.10-14.95
EPS (Diluted)
-2.86-3.78-23.10-14.95
Free Cash Flow
-88.09-67.23-28.82-3.85
Free Cash Flow Per Share
-2.26-3.24-19.14-4.95
EBITDA
-124.08-82.22-36.07-5.84
D&A For EBITDA
1.020.840.110.02
EBIT
-125.1-83.06-36.18-5.85
Source: S&P Capital IQ. Standard template. Financial Sources.